Which Healthcare ETF Is Best for the Long Term: State Street’s XPH or Invesco’s PBE?
The State Street SPDR S&P Pharmaceuticals ETF (NYSEMKT:XPH) offers broader exposure and lower expenses, while the Invesco Biotechnology & Genome ETF (NYSEMKT:PBE) provides a concentrated, higher-yielding strategy focused on biotech momentum. Investors seeking healthcare exposure may choose between specialized niches. This comparison looks at how the broader pharmaceutical focus of XPH contrasts with the factor-based biotechnology approach of PBE. While both target healthcare innovators, their portfolio construction and cost structures result in different risk profiles for investors. Beta measures price volatility relative to the S&P 500; beta is calculated from monthly returns over the available fund history (up to five years). The 1-yr return represents total return over the trailing 12 months. Dividend yield is the trailing-12-month distribution yield. Continue reading